39.35
2.97 (8.16%)
| Penutupan Terdahulu | 36.38 |
| Buka | 36.46 |
| Jumlah Dagangan | 418,305 |
| Purata Dagangan (3B) | 384,492 |
| Modal Pasaran | 1,836,737,792 |
| Harga / Jualan (P/S) | 17.37 |
| Harga / Buku (P/B) | 4.64 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Nov 2026 |
| Margin Operasi (TTM) | -11,831.05% |
| EPS Cair (TTM) | -1.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -30.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.25% |
| Nisbah Semasa (MRQ) | 32.19 |
| Aliran Tunai Operasi (OCF TTM) | -74.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.69 M |
| Pulangan Atas Aset (ROA TTM) | -17.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Septerna, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -0.33 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.64% |
| % Dimiliki oleh Institusi | 105.46% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |